Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Molecular Basis Of Minimal Residual Disease In Subtypes Of Pediatric B Cell Acute Lymphoblastic Leukemia

Jitsuda Sitthi-Amorn, MD, Betty Herrington, MD, Gail Megason, MD, Jeanette Pullen, MD, Catherine Gordon, MD, Shirley Hogan, Pharm.D, Tejaswi Koganti, MS, Chindo Hick, PhD

Blood (2013) 122 (21): 1390.

https://doi.org/10.1182/blood.V122.21.1390.1390

Published: 2013

Journal Articles

Outcome modeling with CRLF2, IKZF1, JAK , and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study

Blood (2012) 119 (15): 3512–3522.

https://doi.org/10.1182/blood-2011-11-394221

Published: 2012

Includes: Supplemental data

Journal Articles

Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)

Barbara L. Asselin, Meenakshi Devidas, Chenguang Wang, Jeanette Pullen, Michael J. Borowitz, Robert Hutchison, Steven E. Lipshultz, Bruce M. Camitta

Blood (2011) 118 (4): 874–883.

https://doi.org/10.1182/blood-2010-06-292615

Published: 2011

Journal Articles

Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group

Kelly W. Maloney, William L. Carroll, Andrew J. Carroll, Meenakshi Devidas, Michael J. Borowitz, Paul L. Martin, Jeanette Pullen, James A. Whitlock, Cheryl L. Willman, Naomi J. Winick, Bruce M. Camitta, Stephen P. Hunger

Blood (2010) 116 (7): 1045–1050.

https://doi.org/10.1182/blood-2009-07-235291

Published: 2010

Journal Articles

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

Michael J. Borowitz, Meenakshi Devidas, Stephen P. Hunger, W. Paul Bowman, Andrew J. Carroll, William L. Carroll, Stephen Linda, Paul L. Martin, D. Jeanette Pullen, David Viswanatha, Cheryl L. Willman, Naomi Winick, Bruce M. Camitta

Blood (2008) 111 (12): 5477–5485.

https://doi.org/10.1182/blood-2008-01-132837

Published: 2008

Includes: Supplemental data

Journal Articles

Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).

Naomi Winick, MD, Paul L. Martin, MD, PhD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Michael J. Borowitz, MD, PhD, Paul Bowman, MD, Eric Larsen, MD, Jeanette Pullen, MD, Stephen P. Hunger, MD, William L. Carroll, MD, Bruce M. Camitta, MD

Blood (2007) 110 (11): 583.

https://doi.org/10.1182/blood.V110.11.583.583

Published: 2007

Journal Articles

Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201

Allen R. Chauvenet, Paul L. Martin, Meenakshi Devidas, Stephen B. Linda, Beverly A. Bell, Joanne Kurtzberg, Jeanette Pullen, Mark J. Pettenati, Andrew J. Carroll, Jonathan J. Shuster, Bruce Camitta

Blood (2007) 110 (4): 1105–1111.

https://doi.org/10.1182/blood-2006-12-061689

Published: 2007

Includes: Supplemental data

Journal Articles

Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study.

Jeffrey Rubnitz, MD, PhD, David Wichlan, MS, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Joanne Kurtzberg, MD, Beverly Bell, MD, Stephen Hunger, MD, Allen Chauvenet, MD, Ching-Hon Pui, MD, Bruce Camitta, MD, Jeanette Pullen, MD

Blood (2006) 108 (11): 218.

https://doi.org/10.1182/blood.V108.11.218.218

Published: 2006

Journal Articles

Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study.

Michael J. Borowitz, MD, PhD, Meenakshi Devidas, PhD, W. Paul Bowman, MD, William L. Carroll, MD, I.-Ming Chen, MD, Richard Harvey, PhD, Stephen Hunger, MD, Paul L. Martin, Jeanette Pullen, MD, David Viswanatha, MD, Cheryl L. Willman, MD, Naomi Winick, MD, Bruce Camitta, MD

Blood (2006) 108 (11): 219.

https://doi.org/10.1182/blood.V108.11.219.219

Published: 2006

Journal Articles

Changes in the Delivery of Standard Chemotherapeutic Agents during Induction Affect Early Measures of Minimal Residual Disease (MRD): POG 9900 for Patients with B-Precursor Low and Standard Risk ALL.

Naomi Winick, Michael J. Borowitz, Mini Devidas, Paul L. Martin, Jeanette Pullen, Stephen P. Hunger, William L. Carroll, Bruce Camitta

Blood (2006) 108 (11): 2272.

https://doi.org/10.1182/blood.V108.11.2272.2272

Published: 2006

Journal Articles

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)

Kirk R. Schultz, D. Jeanette Pullen, Harland N. Sather, Jonathan J. Shuster, Meenakshi Devidas, Michael J. Borowitz, Andrew J. Carroll, Nyla A. Heerema, Jeffrey E. Rubnitz, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Stephen P. Hunger, William L. Carroll, Paul S. Gaynon, Bruce M. Camitta

Blood (2006) 109 (3): 926–935.

https://doi.org/10.1182/blood-2006-01-024729

Published: 2006

Journal Articles

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

Beverly A. Bell, MD, Sharon B. Abish, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Jeanette Pullen, MD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 875.

https://doi.org/10.1182/blood.V106.11.875.875

Published: 2005

Journal Articles

Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.

Megan A. Rice, Beverly A. Bell, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Sharon B. Abish, MD, Jeanette Pullen, MD, Meenakshi Devidas, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 880.

https://doi.org/10.1182/blood.V106.11.880.880

Published: 2005

Journal Articles

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Stephen Rodes, BS, Beverly A. Bell, MD, Sharon B. Abish, MD, Jeanette Pullen, MD, Allen Chauvenet, MD, Joanne Kurtzberg, MD, Meenakshi Devidas, PhD, Jonathan Shuster, PhD, Bruce M. Camitta, MD

Blood (2005) 106 (11): 882.

https://doi.org/10.1182/blood.V106.11.882.882

Published: 2005

Journal Articles

Prognostic Significance of Minimal Residual Disease (MRD) in Children with High Risk Acute Lymphoblastic Leukemia(ALL) A Children’s Oncology Group Study.

Michael J. Borowitz, MD, PhD, Meenakshi Devidas, PhD, W. Paul Bowman, MD, Eric Larsen, MD, Jeanette Pullen, MD, Bruce Camitta, MD

Blood (2005) 106 (11): 85.

https://doi.org/10.1182/blood.V106.11.85.85

Published: 2005

Journal Articles

Perforin Polymorphism A91V and Susceptibility to Childhood Acute Lymphoblastic Leukemia (ALL).

Parinda A. Mehta, MD, Stella M. Davies, MBBS, Ashish Kumar, MD, Meenakshi Devidas, PhD, Susan Lee, BS, Tiffany Wilke, BS, James Elliott, BS, MBA, Joyce Villanueva, BS, Jeanette Pullen, MD, Yetnayet Zewge, Alexandra H. Filipovich, MD

Blood (2005) 106 (11): 1453.

https://doi.org/10.1182/blood.V106.11.1453.1453

Published: 2005

Journal Articles

Comparison of Diagnostic and Relapse Flow Cytometry Phenotypes in Childhood ALL: Implications for Residual Disease (MRD) Detection.

Michael J. Borowitz, MD PhD, D. Jeanette Pullen, MD, Naomi Winick, MD, P. L. Martin, MD, W. Paul Bowman, MD, Bruce Camitta, MD

Blood (2004) 104 (11): 1091.

https://doi.org/10.1182/blood.V104.11.1091.1091

Published: 2004

Journal Articles

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Kirk R. Schultz, MD, Jeanette Pullen, MD, Harland Sather, PhD, Jonathan Shuster, PhD, Michael J. Borowitz, MD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Paul S. Gaynon, MD, Bruce M. Camitta, MD

Blood (2004) 104 (11): 519.

https://doi.org/10.1182/blood.V104.11.519.519

Published: 2004

Journal Articles

New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group report of 343 cases

Nancy R. Schneider, Andrew J. Carroll, Jonathan J. Shuster, D. Jeanette Pullen, Michael P. Link, Michael J. Borowitz, Bruce M. Camitta, Julie A. Katz, Michael D. Amylon

Blood (2000) 96 (7): 2543–2549.

https://doi.org/10.1182/blood.V96.7.2543

Published: 2000

Journal Articles

E2A-PBX1 Chimeric Transcript Status at End of Consolidation Is Not Predictive of Treatment Outcome in Childhood Acute Lymphoblastic Leukemias With a t(1;19)(q23;p13): A Pediatric Oncology Group Study

Stephen P. Hunger, Majilinde Z. Fall, Bruce M. Camitta, Andrew J. Carroll, Michael P. Link, Stephen J. Lauer, Donald H. Mahoney, D. Jeanette Pullen, Jonathan J. Shuster, C. Philip Steuber, Michael L. Cleary

Blood (1998) 91 (3): 1021–1028.

https://doi.org/10.1182/blood.V91.3.1021

Published: 1998

NARROW

Molecular Basis Of Minimal Residual Disease In Subtypes Of Pediatric B Cell Acute Lymphoblastic Leukemia

Outcome modeling with CRLF2, IKZF1, JAK , and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study

Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)

Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).

Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201

Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children’s Oncology Group Study.

Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study.

Changes in the Delivery of Standard Chemotherapeutic Agents during Induction Affect Early Measures of Minimal Residual Disease (MRD): POG 9900 for Patients with B-Precursor Low and Standard Risk ALL.

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)

A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.

Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.

A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.

Prognostic Significance of Minimal Residual Disease (MRD) in Children with High Risk Acute Lymphoblastic Leukemia(ALL) A Children’s Oncology Group Study.

Perforin Polymorphism A91V and Susceptibility to Childhood Acute Lymphoblastic Leukemia (ALL).

Comparison of Diagnostic and Relapse Flow Cytometry Phenotypes in Childhood ALL: Implications for Residual Disease (MRD) Detection.

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group report of 343 cases

E2A-PBX1 Chimeric Transcript Status at End of Consolidation Is Not Predictive of Treatment Outcome in Childhood Acute Lymphoblastic Leukemias With a t(1;19)(q23;p13): A Pediatric Oncology Group Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only